Clearpoint Neuro Inc (CLPT) Stock Analysis

Verdict: AVOID

Widening quarterly cash burn and 4 consecutive earnings misses render 25.9% revenue growth unattractive until -81.8% net losses stabilize.

Investment score: 29/100

Analysis as of

Is Clearpoint Neuro Inc stock worth reviewing? AI model thesis

Clearpoint Neuro faces structural profit headwinds with operating margins of -73.42% and 4 consecutive EPS misses. Despite $45.92M cash (~22.5 months runway) and 25.86% revenue growth, $58.23M debt and accelerating FCF burn (-$24.45M) present excessive downside risk at $10.50.

7-factor investment score

Clearpoint Neuro Inc opportunities and risks

What speaks for CLPT

What speaks against CLPT

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
CLPTn/a7.4xn/a62.6%-81.8%-10.0%
OFIXn/a0.4x5.4x69.6%-7.4%-7.5%
CVn/a23.8xn/a50.9%-214.7%-8.4%
OBIOn/a10.9xn/a99.3%-184.6%-17.0%
MOBIn/a11.1xn/a82.8%-151.6%-12.3%
Peer mediann/a11.0xn/a76.2%-168.1%-10.4%

Frequently asked questions about Clearpoint Neuro Inc (CLPT)

Is CLPT stock a good investment?

The cached TradeMates AI model rates Clearpoint Neuro Inc as AVOID with an investment score of 29/100. Clearpoint Neuro faces structural profit headwinds with operating margins of -73.42% and 4 consecutive EPS misses. Despite $45.92M cash (~22.5 months runway) and 25.86% revenue growth, $58.23M debt and accelerating FCF burn (-$24.45M) present excessive downside risk at $10.50. This is algorithmic model output, not personal investment advice.

Is CLPT stock a buy?

The TradeMates model verdict for CLPT is AVOID with an investment score of 29/100. Treat this as a model signal to review, not a personal buy recommendation.